Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.
More Stories
Fed starts rate-cutting cycle with a bang — but wants it to be the only one
The Federal Reserve cut its policy interest rate by half of a percentage point on Wednesday, a more aggressive move...
Small-cap stocks’ bullish ‘Fed day’ performance reflects investors’ confidence in the economy
Stocks reacted erratically to the Federal Reserve’s bulky 50-basis-point interest-rate cut on Wednesday. But by the time the dust had...
Bond market gets a Fed wake-up call after pricing in a recession
Long-term yields rose even though the Federal Reserve took a big bite out of interest rates on Wednesday. Here’s why.
Bitcoin stays above $60,000 after Fed’s jumbo rate cut. Here’s what to watch next.
A weekly look at the most important news and moves in crypto, and what’s on the horizon in digital assets.
Steelcase says big corporate customers are ordering less office furniture
Shares of Steelcase Inc. fell after hours on Wednesday after the office-furniture maker’s third-quarter sales outlook came up short of...
Moody’s lifts outlook on four big regional banks to stable from negative
The debt outlook for Fifth Third Bancorp, First Citizens Bancshares Inc., Regions Financial Corp. and Huntington Bancshares Inc. has been...